

Size : 2.5 x 5 Inch

Pantoprazole Capsules

ULPAN-40 ER

Prescription only medicines

Composition

Each hard gelatin capsule contains:

Pantoprazole Sodium Sesquihydrate BP equivalent to Pantoprazole (as enteric coated pellets)	40 mg
Excipients	Q.S
Approved colours used in empty capsule shell	

Pharmacological properties

Pharmacodynamic properties

Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC02

Mechanism of action: Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells. Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H⁺, K⁺-ATPase enzyme. As with other proton pump inhibitors and H₂ receptor inhibitors, treatment with Pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity.

Pharmacokinetic properties

Absorption: Pantoprazole is rapidly absorbed and the maximal plasma concentration is achieved even after one single 40 mg oral dose. On average at about 2.5 h p.a. the maximum serum concentrations of about 2 - 3 µg/ml are achieved, and these values remain constant after multiple administration.

Distribution: Pantoprazole's serum protein binding is about 98 %. Volume of distribution is about 0.15 l/kg

Metabolism and Elimination: The substance is almost exclusively metabolized in the liver. Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. Renal elimination represents the major route of excretion (about 80 %) for the metabolites of Pantoprazole; the rest is excreted with the faeces.

Indications

For treatment of Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Gastric and duodenal ulcers, H. pylori associated ulcers and pathological hypersecretory conditions.

Posology and method of administration

One capsule daily or use as directed by the Physician.

Method of administration: Capsule should not be chewed or crushed, and should be swallowed whole, 1 hour before meal with some water.

Contraindications: Hypersensitivity to the active substance.

Warnings and precautions for use

Hepatic Impairment: In patients with severe liver impairment, the liver enzymes should be monitored regularly during treatment with Pantoprazole, particularly on long-term use.

Long term treatment: In long-term treatment, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.

Gastrointestinal infections caused by bacteria: Treatment with Pantoprazole may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and Campylobacter and C. difficile.

Hypomagnesaemia: Severe hypomagnesaemia has been reported in patients treated with PPIs like Pantoprazole for at least three months, and in most cases for a year.

Bone fractures: Proton pump inhibitors, especially if used in high doses and over long durations (> 1 year), may modestly increase the risk of hip, wrist and spine fracture.

Drug interactions

HIV medications (Atazanavir): Co-administration of Atazanavir and other HIV medications whose absorption is pH-dependent with proton-pump inhibitors might result in a substantial reduction in the bioavailability and efficacy.

Methotrexate: Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients.

Other interactions studies: Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. Interaction studies with drugs also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and Ethinyl oestradiol did not reveal clinically significant interactions.

Pregnancy and lactation

Pregnancy: There are no adequate data from the use of Pantoprazole in pregnant women. Pantoprazole should not be used during pregnancy unless clearly necessary.

Breast-feeding: Excretion of Pantoprazole into human milk has been reported. Therefore a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Pantoprazole should be made taking into account the benefit of breast-feeding to the child and the benefit of Pantoprazole therapy to women.

Side effects

The most commonly reported ADRs are diarrhoea and headache.

Uncommon: Sleep disorders, Headche, Dizziness, Diarrhoea, Abdominal distension and bloating, Constipation, Dry mouth, Abdominal pain and discomfort, Liver enzymes increased (transaminases, γ -GT), Rash/exanthema/eruption, Pruritus, Asthenia, fatigue and malaise.

Rare: Agranulocytosis, Hypersensitivity, Hyperlipidaemias and lipid increases (triglycerides, cholesterol), Weight changes, Angioedema, Arthralgia, Myalgia, Gynaecomastia, Body temperature increased, edema peripheral

Very Rare: Thrombocytopenia, Leukopenia, Pancytopenia, Disorientation (and all aggravations)

Overdosage and its Treatment

There are no known symptoms of overdose in humans. In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.

Storage condition: Store below 30 °C. Protect from light and moisture.

Keep out of the reach and sight of children.

SHELF LIFE: 24 months

PRESENTATION: 3 Alu/Alu Blisters of 10 capsules in a printed carton with a package insert.

Marketed by: **Sun Enterprises Ltd.**
B.P.933, Quarter Commercial,
Street KN 70 Kigali, Rwanda.

Manufactured in India by :
CORONA
Remedies Pvt. Ltd.

Village. Jatoli, Post Office - Oachghat,
Tehsil Solan, Dist. Solan (H.P.)-173 223.INDIA

RW-SE

Front

Back